A CE assay for the simultaneous determination of charged and uncharged potential impurities (1S,2S-(1)-norpseudoephedrine, 1R,2S-(À)-norephedrine, phenylacetone and phenylacetone oxime) of dexamphetamine sulfate including the stereoisomer levoamphetamine was developed and validated. The optimized background electrolyte consisted of a 50 mM sodium phosphate buffer, pH 3.0, containing 80 mg/mL sulfobutylether-b-CD and 25 mg/mL sulfated b-CD. Separations were performed in 40.2/35 cm, 50 mm id fused-silica capillaries at a temperature of 201C and an applied voltage of -10 kV. 1R,2S-(À)-ephedrine was used as internal standard. The assay was validated in the range of 0.05-1.0% for the related substances and in the range of 0.05-5.0% for levoamphetamine. The LOD was 0.01-0.02% depending on the analyte. The assay also allowed the separation of the E,Z-stereoisomers of phenylacetone oxime. The effect of the degree of substitution of sulfobutylether-b-CD was investigated. In commercial samples of dexamphetamine sulfate between 3.2 and 3.7% of levoamphetamine were found. Furthermore, phenylacetone and phenylacetone oxime could be observed at the LOD, indicating the synthetic origin of the investigated samples. The effect in attention deficit hyperactivity disorder is believed to be mediated via several mechanisms including the binding of the drug to the pre-synaptic dopamine transporter inducing a reversed transport process as well as stimulation of pre-synaptic inhibitory autoreceptors, resulting in reduced activity in dopaminergic and noradrenergic pathways [4]. Dexamphetamine can be synthesized by various methods, for example, starting from chiral precursors such as D-phenylalanine [5] or from chiral b-hydroxyphenylethylamines such as 1R,2S-(À)-norephedrine or 1S,2S-(1)-norpseudoephedrine [6,7]. Alternatively, the compound can be obtained from racemic amphetamine synthesized from phenylacetone (1-phenyl-2-propanone, benzyl methyl ketone) by Leuckart reaction or by reduction of the oxime [8,9] followed by fractional crystallization with L-(1)-tartaric acid [10]. Thus, charged as well as neutral starting materials or synthetic by-products as well as the enantiomer levoamphetamine (2R-(À)-amphetamine) may be present as related substances in the drug.Dexamphetamine sulfate is described in monographs by the United States Pharmacopeia 32 (USP 32) [11]